Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY

Innoviva, Inc.

2023-FY EPS reported $2.20 revenue$310,463,000

Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.
Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).
Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.
XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.
Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Innoviva, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net income was $61.5 million, or $0.97 basic per share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net income was $61.5 million, or $0.97 basic per share
Result: reported results

Exact text from the filing

On February 29, 2024, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-029378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.